Analysts expect Pacific Biosciences of California to report Q2 2026 revenue of $41.0 million and a net loss of $0.14 per share, with the stock currently trading at $1.40 against an average analyst target of $2.38.
The central focus for investors remains the adoption rate of the flagship Revio sequencing system and whether consumable pull-through can drive meaningful margin expansion. Management’s ability to defend its full-year 2026 revenue guidance of $165 million to $175 million is critical following a recent history of funding constraints in the academic and government sectors.
Investors are also closely watching for progress toward the company's ambitious non-GAAP gross margin target of 41% to 44% as ongoing cost-cutting initiatives and supply chain optimizations take hold.